ArticleFrontiers in immunology2025

Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.

Dongjuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.